Ophthalmology

Oncology, Ophthalmology Biosimilars Progress in Europe

September 19th 2022

By Skylar Jeremias

As the United Kingdom adds another oncology biosimilar to its collection, the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion for another ranibizumab candidate.

European Commission Approves Second Lucentis Biosimilar

August 29th 2022

By Skylar Jeremias

Article

The European Commission granted marketing authorization to Teva’s ranibizumab biosimilar (Ranivisio), the second ophthalmology biosimilar and the second biosimilar to reference Lucentis to be approved in the European Union.

FDA Approves Coherus’ Cimerli as Interchangeable Biosimilar to Ranibizumab

August 3rd 2022

By The Center for Biosimilars

Article

Another ranibizumab biosimilar, Byooviz, is approved, but Coherus’ product is the first deemed interchangeable, which involves additional FDA requirements that allow substitution without intervention of the prescribing clinician.

Biosimilars Check-In: Celltrion Pushes for Yuflyma in Europe; Xbrane Updates on Ranibizumab Filing

July 21st 2022

By Skylar Jeremias

Article

In recent weeks, Celltrion Healthcare furthered its adalimumab biosimilar (Yuflyma) by launching the drug in Spain and Portugal and starting a clinical trial in France while Xbrane Biopharma provided an update on the FDA filing of its ranibizumab biosimilar.

New Biosim on the Block: Dr Sonia Oskouei Discusses the US Launch of Byooviz, the First Ophthalmology Biosimilar

July 10th 2022

By Skylar Jeremias

Podcast

On this episode of Not So Different, we spoke with Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health, to discuss the US launch of Byooviz, the first ophthalmology biosimilar in the United States, and how it's expected to impact ophthalmology care.

One Aflibercept Trial Begins; Another Insulin Recall

July 7th 2022

By Skylar Jeremias

Article

As Alvotech announced that dosing of patients with its aflibercept biosimilar candidate has begun, Viatris announces its third recall for a batch of its insulin glargine biosimilar over missing labels.

First Ophthalmology Biosimilar Launches in US

June 2nd 2022

By Skylar Jeremias

Article

Samsung Bioepis and Biogen announced that Byooviz has launched on the US market as the first ranibizumab biosimilar referencing Lucentis, listed at a 40% discount compared with the originator.

Dr Sonia Oskouei Predicts How Bevacizumab Use Will Evolve in Ophthalmology

May 22nd 2022

By Skylar Jeremias

Video

The use of bevacizumab products for ophthalmic conditions will continue to evolve as the market grows. However, off-label usage will likely be the norm, according to Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health, at Asembia’s Specialty Pharmacy Summit.

Teva’s Lucentis Biosimilar Gains UK Approval

May 17th 2022

By Skylar Jeremias

Article

The United Kingdom has approved Teva Pharmaceutical’s biosimilar (Ongavia) that references Lucentis (ranibizumab) for the treatment of several ophthalmic conditions.

Dr Sonia Oskouei Describes the Need for More Biosimilar Education for Ophthalmologists

May 8th 2022

By Skylar Jeremias

Video

Although the United States is looking to be one of the first countries to market an ophthalmology biosimilar, more education is needed to convince ophthalmologists of the safety and efficacy of biosimilars, said Cardinal Health's Sonia T. Oskouei, PharmD, BCMAS, DPLA.